EGFR and neoplasm: We speculate that EGFR-TKIs and PD-1/PD-L1 inhibitors block PI3K/AKT/mTOR signaling, which blocks the absorption of essential amino acids by tumor cells, resulting in increased phenylalanine, n-acetyl-l-leucine, and n-acetyl-d-tryptophan.